Brendan Smith
Stock Analyst at TD Cowen
(1.97)
# 3,096
Out of 5,067 analysts
9
Total ratings
50%
Success rate
5.22%
Average return
Main Sectors:
Stocks Rated by Brendan Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Maintains: Hold | $8 → $7 | $6.47 | +8.19% | 2 | Nov 4, 2025 | |
| WST West Pharmaceutical Services | Initiates: Buy | $350 | $271.07 | +29.12% | 1 | Oct 29, 2025 | |
| SLP Simulations Plus | Initiates: Hold | $16 | $17.00 | -5.88% | 1 | Sep 30, 2025 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Buy | $3 → $10 | $8.17 | +22.40% | 1 | Sep 20, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $59 → $65 | $70.34 | -7.59% | 2 | Aug 7, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Outperform | n/a | $40.45 | - | 1 | Jul 21, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | n/a | $18.00 | - | 1 | Dec 5, 2022 |
Novavax
Nov 4, 2025
Maintains: Hold
Price Target: $8 → $7
Current: $6.47
Upside: +8.19%
West Pharmaceutical Services
Oct 29, 2025
Initiates: Buy
Price Target: $350
Current: $271.07
Upside: +29.12%
Simulations Plus
Sep 30, 2025
Initiates: Hold
Price Target: $16
Current: $17.00
Upside: -5.88%
Ginkgo Bioworks Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $3 → $10
Current: $8.17
Upside: +22.40%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Buy
Price Target: $59 → $65
Current: $70.34
Upside: -7.59%
Arrowhead Pharmaceuticals
Jul 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $40.45
Upside: -
Denali Therapeutics
Dec 5, 2022
Initiates: Outperform
Price Target: n/a
Current: $18.00
Upside: -